Skip to main content
Premium Trial:

Request an Annual Quote

Polish University Taps IBM's Blue Gene Supercomputer to Support Biomedical Research Initiative


The University of Warsaw's Interdisciplinary Center for Mathematical and Computational Modeling had selected IBM's Blue Gene/Q Supercomputer to support a biomedical and biotechnological research initiative aimed at developing new drugs and therapies for several ailments including neoplastic, neurological, and vascular disease.

The University of Warsaw is leading a consortium called the Center for Pre-clinical Research and Technology, or CEPT, a €100 million ($130 million) project that involves more than 500 life science and biomedical researchers as well as physicians and students from three universities and seven research centers.

They'll be using the supercomputer, which has been named Nostromo, to run analysis algorithms in order to identify rare genetic variants that are associated with chronic conditions such as Alzheimer's disease, cancer, diabetes, downs syndrome, and more and ultimately develop more targeted drugs and treatments.

"Nostromo is able to process up to 16 terabytes of …data per …sequence by running simulations at the speed of 210 trillion operations per second," Ales Bartunek, the country general manager for IBM Poland and Baltics, said in a statement. This should help "save years of research and help scientists take healthcare in Poland to the next level," he said.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.